Candel Therapeutics Announces Equity Offering to Fund CAN-2409
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Candel Therapeutics ( (CADL) ) has shared an announcement.
On February 19, 2026, Candel Therapeutics, Inc. entered into an underwriting agreement to sell 18,348,624 shares of common stock at $5.45 per share, with underwriters granted a 30-day option to buy up to an additional 2,752,293 shares. The registered offering, led by Citigroup, Cantor Fitzgerald, and Stifel, is expected to close on or about February 23, 2026, subject to customary conditions.
Candel expects approximately $93.5 million in net proceeds from the base offering, or up to about $107.6 million if the option is fully exercised, and plans to deploy the capital toward launch readiness, medical affairs, pre-commercialization, and commercial activities for CAN-2409 in early localized prostate cancer, as well as continued funding of the phase 3 trial of CAN-2409 in non-small cell lung cancer and general corporate purposes. Based on assumed net proceeds of $93.5 million, the company estimates its cash and cash equivalents will fund operating and capital needs into the first quarter of 2028, extending its runway and supporting late-stage development and potential commercialization efforts.
The most recent analyst rating on (CADL) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.
Spark’s Take on CADL Stock
According to Spark, TipRanks’ AI Analyst, CADL is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and significant cash burn) despite a stronger, low-leverage balance sheet. Technicals are moderately favorable with price above major moving averages and positive momentum indicators. Valuation remains challenged due to negative earnings, while recent corporate events provide a modest positive offset via improved financing capacity and pipeline visibility.
To see Spark’s full report on CADL stock, click here.
More about Candel Therapeutics
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies designed to elicit individualized, systemic anti-tumor immune responses for cancer patients. Its pipeline includes aglatimagene besadenovec (CAN-2409), based on a genetically modified adenovirus platform, and linoserpaturev from a herpes simplex virus platform, alongside the HSV-based enLIGHTEN Discovery Platform targeting solid tumors.
Aglatimagene is Candel’s lead candidate, having completed phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and a pivotal, placebo-controlled phase 3 trial in localized prostate cancer under a Special Protocol Assessment with the U.S. Food and Drug Administration. The FDA has granted the program multiple designations, including Fast Track in localized prostate cancer and NSCLC, Fast Track and Orphan Drug in PDAC, while linoserpaturev is being evaluated in an ongoing phase 1b trial in recurrent high-grade glioma.
Average Trading Volume: 787,995
Technical Sentiment Signal: Sell
Current Market Cap: $321.2M
For an in-depth examination of CADL stock, go to TipRanks’ Overview page.
